How Stem Cells Support Repair: Signals, Homing and the Role of Age
Most people picture stem cells as spare parts: put new cells in, and they turn into new tissue. Researchers who study one type of stem cell have suggested a different picture. In this view, the cells work more like messengers. They gather where the body is injured and release substances that help it repair itself.
This article looks at four published papers behind that idea: what they found, how strong the evidence is, and what is still unknown.
What mesenchymal stem cells are
Mesenchymal stem cells, often shortened to MSCs, are cells found in connective tissues such as bone marrow and fat. In the lab, MSCs can turn into bone, cartilage, muscle and fat cells (1,2). Researchers have also isolated them from umbilical cord tissue, cord blood and placenta (2).
That ability to become other cell types is called multipotency. For years it was the main reason scientists hoped to use MSCs to rebuild damaged tissue (1). In 2011, Arnold Caplan and Diego Correa argued that this focus missed a question: what do MSCs naturally do inside the body? (1)
Cells that sit beside blood vessels
Part of the answer came from where MSCs live. Almost every blood vessel in the body has cells wrapped around its outer wall. These are called pericytes. When pericytes are isolated and tested, they carry the same surface markers as MSCs (1). Caplan had earlier proposed that all MSCs may in fact be pericytes (1).
This places MSCs beside the blood supply of nearly every tissue, ready to respond when a small vessel is damaged.
The "drugstore" idea
Caplan and Correa proposed a model. When a blood vessel is injured, nearby pericytes are released, become active MSCs and start producing a range of bioactive molecules, natural substances that act on other cells (1).
They grouped these effects into two main types (1):
Immunomodulation. The cells calm the immune response at the injury site. This works through released molecules and through direct contact with immune cells.
Trophic (supportive) effects. The released molecules help limit cell death, especially when tissue has lost its blood supply, and reduce scar formation. They encourage new small blood vessels to form, partly through a growth signal called VEGF (vascular endothelial growth factor). They also prompt the tissue's own repair cells to divide and mature.
Caplan and Correa described MSCs as site-regulated "drugstores" that dispense what a damaged tissue needs (1). Caplan even suggested a new name: Medicinal Signaling Cells (1).
The authors present this as a proposed model built from many earlier studies. It is a way of making sense of the evidence, not a final answer.
Homing: how cells find an injury
If MSCs are given into a vein, how do they reach the right place? Scientists call this process homing. Jeffrey Karp and Grace Teo reviewed the research in 2009. They defined homing as cells stopping inside the blood vessels of a tissue and then crossing the vessel wall (3).
Animal studies suggest that injured or inflamed tissue draws MSCs in. In one mouse study, infused MSCs settled roughly two and a half to three times more in the brain, heart and liver of mice whose tissues had been damaged by radiation, compared with undamaged mice (3). In a rat model of stroke, MRI scans followed human MSCs as they moved over several weeks toward the damaged area of the brain (3).
The cells seem to follow chemical signals called chemokines released by inflamed tissue, attach to adhesion molecules on the vessel wall, and release enzymes that help them pass through it (3).
The same review is open about the gaps. Homing of lab-grown MSCs is inefficient, and many infused cells collect in the lungs, liver and spleen. Lab-grown cells also become larger, so some may simply get stuck in small vessels, and some homing receptors are often lost during lab growth. Researchers are testing ways to improve this (3).
Why donor cells are not quickly rejected
The immune system checks cells for identity tags called HLA (human leukocyte antigen) molecules. Cells from another person usually trigger an attack.
In a 2003 laboratory study, Katarina Le Blanc and colleagues tested bone marrow MSCs from healthy donors (4). The cells carried one type of tag (HLA class I) but not the other (class II) on their surface. When mixed with immune cells from unrelated people, they did not cause those immune cells to multiply. This held even after the MSCs had been turned into bone, cartilage or fat cells, and after exposure to an inflammatory signal. The MSCs also reduced the immune reaction between two other people's cells in the same dish (4).
The authors concluded that their results support transplanting MSCs between people who are not tissue-matched (4). Karp and Teo note the same property, which allows donor MSCs to be given without drugs that suppress the immune system (3). This was a lab study, not a study in patients.
What happens to our own stem cells with age
A 2017 review by Ahmed and colleagues sums up a growing body of research: adult stem cells age with the person (2). Healing slows down. A broken bone, for example, takes longer to mend in older adults than in children (2).
For MSCs, the review describes several changes. The pool of MSCs in bone marrow gets smaller with age. The cells that remain tend to become fat cells rather than bone cells, which may contribute to bone thinning later in life. MSCs from older donors also cope less well with oxidative stress, a kind of chemical wear inside cells. Telomeres, the protective caps on the ends of chromosomes, shorten over time in MSCs as in other stem cells (2).
Caplan and Correa make a related point. For small injuries, the body's own MSCs may be enough. If injuries are large or happen in older people, they suggest the natural supply may need to be supplemented (1). This is one reason researchers are interested in younger sources. MSCs from fat, placenta, umbilical cord and muscle appear similar but not identical, and which source suits which situation has not yet been settled (1).
What the evidence can and cannot tell us yet
These papers give a hopeful picture, but much of it comes from animal studies and lab experiments, and most of the cells studied came from bone marrow rather than umbilical cord. Karp and Teo point out that scientists still do not fully understand how MSCs target specific tissues, where exactly they end up, or what they become once there (3). Caplan and Correa also say more work is needed to define when MSCs should be used and exactly how they act (1). Results in animals do not always carry over to people.
What to talk about with your doctor before starting
If you are considering stem cell therapy, a conversation with a doctor who knows your health history is the place to begin. Useful questions include:
Where do the cells come from, and how are they grown and tested?
How might my current health, my medicines, or a recent infection or injury affect the plan?
What changes are realistic for someone like me, and over what time frame?
How will we track whether anything has changed?
Your doctor decides whether this approach suits you and sets the plan.
For one person's account of ten years of stem cell therapy in Bangkok, read Stem cell therapy in Thailand: ten years of doing it on myself.
Last reviewed: 2 November 2026
References
Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-5. doi:10.1016/j.stem.2011.06.008
Ahmed ASI, Sheng MHC, Wasnik S, Baylink DJ, Lau KHW. Effect of aging on stem cells. World J Exp Med. 2017;7(1):1-10. doi:10.5493/wjem.v7.i1.1
Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206-16. doi:10.1016/j.stem.2009.02.001
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890-6. doi:10.1016/S0301-472X(03)00110-3



Comments